Reported Earlier, Eisai And Biogen Reveal Five-Year Findings On Alzheimer's Treatment Lecanemab At Clinical Trials for Alzheimer's Disease Conference

Biogen Inc. -1.43% Pre

Biogen Inc.

BIIB

174.40

175.06

-1.43%

+0.38% Pre

New testing method highlights link between protofibrils and biomarkers for neurodegeneration-

-Patient and caregiver perspectives on five-year treatment with lecanemab -

- Utilization of blood biomarkers to predict brain amyloid accumulation in AHEAD study of preclinical AD-

Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via